Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

August 31, 2002

Study Completion Date

August 31, 2002

Conditions
Asthma
Interventions
DRUG

Levalbuterol 1.25 mg

"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"

DRUG

Racemic Albuterol Sulfate

"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"

Trial Locations (28)

Unknown

Hoover

Montgomery

Encinitas

Fresno

Oakland

Torrance

Colorado Springs

Gainesville

Jacksonville

Tampa

Chicago

Metairie

Ann Arbor

Detroit

Kansas City

St Louis

Red Bank

Brooklyn

New Hyde Park

Syracuse

Rocky Mount

Akron

Cleveland

Lake Oswego

Medford

Philadelphia

Houston

Salt Lake City

All Listed Sponsors
lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT00667407 - Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma | Biotech Hunter | Biotech Hunter